Segments (Tables)

12 Months Ended

Dec. 31, 2022

Segment Reporting [Abstract]

Information by Reportable Segment

Segment Adjusted EBITDA by reportable segment was as follows:

	Year Ended December 31,
	2022		2021		2020
Biopharmaceuticals	$	(45,039)	$	(45,754)	$	(35,378)
Exemplar	4,997		6,898		4,004
Segment Adjusted EBITDA for operating segments	$	(40,042)	$	(38,856)	$	(31,374)

Revenues by reportable segment were as follows:

	Year Ended December 31, 2022
	Biopharmaceuticals		Exemplar		Total
Revenues from external customers	$	14,894	$	12,015	$	26,909
Intersegment revenues	1,446		—		1,446
Total segment revenues	$	16,340	$	12,015	$	28,355

	Year Ended December 31, 2021
	Biopharmaceuticals		Exemplar		Total
Revenues from external customers	$	922	$	13,345	$	14,267
Intersegment revenues	1,637		—		1,637
Total segment revenues	$	2,559	$	13,345	$	15,904

	Year Ended December 31, 2020
	Biopharmaceuticals		Exemplar		Total
Revenues from external customers	$	21,780	$	10,158	$	31,938
Intersegment revenues	4,797		—		4,797
Total segment revenues	$	26,577	$	10,158	$	36,735

Goodwill by reportable segment was as follows:

	Biopharmaceuticals		Exemplar		Total
Goodwill
Balances at December 31, 2020	$	17,693	$	20,076	$	37,769
Foreign currency translation adjustments	(215)		—		(215)
Balances at December 31, 2021	17,478		20,076		37,554
Foreign currency translation adjustments	(149)		—		(149)
Impairments	(482)		—		(482)
Balances at December 31, 2022	$	16,847	$	20,076	$	36,923

Reconciliation of Operating Profit (Loss) from Segments to Consolidated

The table below reconciles Segment Adjusted EBITDA for reportable segments to consolidated net loss from continuing operations before income taxes:

	Year Ended December 31,
	2022		2021		2020
Segment Adjusted EBITDA for reportable segments	$	(40,042)	$	(38,856)	$	(31,374)
All Other Segment Adjusted EBITDA			—		—
Remove cash paid for capital expenditures, net of proceeds from sale of assets, and cash paid for investments in affiliates	1,362		2,483		605
Add recognition of previously deferred revenue associated with upfront and milestone payments	16,007		2,034		25,005
Other expenses:
Interest expense	(6,774)		(18,755)		(18,209)
Depreciation and amortization	(7,191)		(8,139)		(8,292)
Loss from disposals of assets			(53)		(50)
Impairment losses	(1,120)		(543)		(814)
Stock-based compensation expense	(10,197)		(13,554)		(19,008)
Adjustment related to accrued bonuses paid in equity awards	1,698		—		2,833
Equity in net loss of affiliates	861		(3)		(603)
Other	(105)		(19)		11
Unallocated corporate costs	(32,913)		(33,506)		(48,915)
Eliminations	(1,552)		(2,056)		(5,713)
Consolidated loss from continuing operations before income taxes	$	(79,966)	$	(110,967)	$	(104,524)

Reconciliation of Revenue from Segments to Consolidated

The table below reconciles total segment revenues from reportable segments to total consolidated revenues:

	Year Ended December 31,
	2022		2021		2020
Total segment revenues from reportable segments	$	28,355	$	15,904	$	36,735
Other revenues, including from other operating segments	—		—		54
Elimination of intersegment revenues	(1,446)		(1,637)		(4,797)
Total consolidated revenues	$	26,909	$	14,267	$	31,992